Bringing the fundamentals into focus…
Back to Clinuvel Pharmaceuticals Limited
How Clinuvel Pharmaceuticals Limited stacks up
CUVL · against 1,216 other Healthcare companies
Growth
35/ 100
Below the middle of the pack.
Ranked #786 of 1,217 · scores higher than 35% of peers
Bars: peers in each 10-point band of the growth score122 peers with a growth score of 30–39, including CUVL · Click a bar to see the companies
Why growth scores 35?
Weighted metrics compared with all Healthcare companies.Mainly because of its revenue growth and earnings per share growth, which are weaker than most Healthcare peers.
- slower revenue growth over the last year: weaker than 72% of peers. Revenue growth: -1.0% vs peer median 6.1%
- slower growth in earnings per share: weaker than 67% of peers. Earnings per share growth: -7.0% vs peer median 9.8%
- 3-year revenue growth is close to the peer norm. 3-year revenue growth: 6.3% vs peer median 5.8%
Metric by metric
Position: dot = CUVL, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | CUVL | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Revenue growthHigher is better · 1,243 reported | -1.0% | 6.1% | 28% | 33% | |
| Earnings per share growthHigher is better · 682 reported | -7.0% | 9.7% | 33% | 33% | |
| 3-year revenue growthHigher is better · 1,192 reported | 6.3% | 5.8% | 51% | 33% |
Ranking by growth score
Top 5 and the companies ranked around CUVL| Rank | Company | Market cap | Growth | Overall |
|---|---|---|---|---|
| 1 | 3.1B EUR (≈$3.4B) | 100 | 100 | |
| 1 | 464M USD | 100 | 53 | |
| 3 | 8.9B HKD (≈$1.1B) | 99 | 61 | |
| 3 | 1.8B HKD (≈$224M) | 99 | 59 | |
| 3 | 7.2B TWD (≈$224M) | 99 | 41 | |
| 786 | 31.1B TWD (≈$965M) | 35 | 63 | |
| 786 | 263.1B JPY (≈$1.8B) | 35 | 72 | |
| 786 | 1.5B SGD (≈$1.1B) | 35 | 60 | |
| 786 | 356M AUD (≈$235M) | 35 | 81 | |
| 786 | 256M USD | 35 | 80 | |
| 786 | 2.0B USD | 35 | 27 | |
| 786 | 27M USD | 35 | 24 | |
| 786 | 6.1B SEK (≈$614M) | 35 | 45 | |
| 798 | 5.8B CNY (≈$807M) | 34 | 67 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score